Sandoz Articles
Mylan seeks more generic market share
7 April 2008
Watson swings to profit of $38.4M in 4th qtr
3 March 2008
J&J/Actavis recall US lots of fentanyl patches
25 February 2008
GPhA board changes
18 February 2008
UPDATE: Raids on major drugmakers as EU Commission starts pharma sector inquiry with unannounced inspections
21 January 2008
Barr unit sues Watson and Sandoz over Seasonale patent
24 December 2007
Stock Commentary - Europe - week to Nov 12, 2007
19 November 2007
German drug discounts facing legal hurdles
19 November 2007
Headlines 25 years ago this week....
22 October 2007
UPDATE: Sandoz' biosimilar epoetin cleared in EU
10 September 2007
Sandoz gets EU approval for biosimilar epoetin alfa
10 September 2007
Sandoz debut generic Toprol in USA
13 August 2007
Headlines 25 years ago this week....
30 July 2007
Aurobindo targets $1B income in next 3 years
9 July 2007
Teva resumes shipment of generic Lotrel in USA
18 June 2007
Sandoz gains FDA appro for generic Toprol
28 May 2007
Merck KGaA generics flourishing in France
19 March 2007
Hungary issues list of non-pharmacy OTCs
29 January 2007
Diovan, Glivec and generics drive Novartis growth in 2006
22 January 2007
Savient files patent suit against Sandoz
11 December 2006
AstraZeneca authorizes US generic Toprol-XL
27 November 2006
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Headlines 25 years ago this week....
23 October 2006
Less price flexibility, more innovation: the market dynamics of targeted therapeutics
16 October 2006
Lek to construct 6.7M euro biopharma site
9 October 2006
ProStrakan half-year sales up 28% to L16.1M
25 September 2006
Fresenius Kabi licenses HESylation platform to Sandoz
28 August 2006
Sandoz and Momenta to collaborate on generics R&D
31 July 2006
Barr settles Novartis suit for $22.5M
13 June 2006
Teva sets up in Japan
29 May 2006
Sandoz plans five more "biosimilars" launches
22 May 2006
Only Actavis seems to be interested in Pliva
15 May 2006
Headlines 25 years ago this week....
8 May 2006
Headlines 25 years ago this week....
1 May 2006
EC approves Sandoz' Omnitrope
24 April 2006
Japan's generic growth attracts foreign firms
27 March 2006
India's "big pharma" is now the target
27 February 2006
Japan/China generic growth opportunities
20 February 2006
Pfizer takes action against Teva and Sandoz over azithromycin
20 February 2006
GLSV finances new antibiotic R&D firm, Nabriva
6 February 2006
EMEA opens the doors for "biosimilars" with Omnitrope
6 February 2006
Generics market takes off in France
6 February 2006
CHMP gives nod to Sandoz' Omnitrope
6 February 2006
Germany's Stada to launch generic EPO
30 January 2006
Novartis sees strong performance with record results in 2005
30 January 2006
Novartis suit seeks FDA ruling on follow-on HGH
19 September 2005
John Sedor: president of Bentley
5 September 2005
York Pharma names Neil Symmonds sales and marketing director
5 September 2005
Novartis bids $4.5B to buy rest of Chiron
5 September 2005
Momenta files ANDA for M-Enoxaparin
5 September 2005
Generics firms taking more aggressive stance, says report
15 August 2005
Florida sues generics firms over Medicaid "scam"
1 August 2005
Matraix recruits Sanjeev Sethi as senior VP
27 June 2005
EU clears Novartis' acquisition of Hexal
6 June 2005
Novartis to relocate Sandoz to Germany
26 April 2005
Florida sues three firms for Medicaid "fraud"
18 April 2005
Novartis gives update on generics acquisitions
18 April 2005
Sandoz plans to sell generic drugs to Spain's hospitals
11 April 2005
Kendle names Andrew Babington VP, European sales
4 April 2005
Stock Commentary - Europe
28 February 2005
Amarin wins domestic approval for Fentanyl TDS
28 February 2005
Novartis seeks German generics buy
14 February 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Editor's views on "Big Pharma" in 2004
10 January 2005
Novartis set to reintegrate Sandoz generics unit
22 November 2004
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
